Skip to main content
Premium Trial:

Request an Annual Quote

Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study

NEW YORK – Personalis said today that it will employ its ImmunoID NeXT platform in an ovarian cancer study spearheaded by the University of New Mexico Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care.

The effort, being conducted at several centers across the US, will employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response to a combination of AstraZeneca's olaparib (Lynparza) and tremelimumab in women with recurrent BRCA-deficient ovarian cancers. According to the company, the trial design reflects evidence from earlier studies showing that immune priming with targeted cytotoxic therapy using a PARP inhibitor might sensitize ovarian tumors to added immune therapy.

According to Personalis, the ImmunoID NeXT system provides broad interrogation of both DNA and RNA across approximately 20,000 genes to identify biomarker signals associated with a variety of biologic features, including tumor escape mechanisms, immune repertoire profiles, neoantigen load, tumor mutational burden, microsatellite instability, oncoviruses, and immune checkpoint gene expression.

Financial terms of the study partnership with UNM were not disclosed.